Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

33.7K
Overview
33.7K
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

182
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
182
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

112
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

147
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
147
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

182
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
182

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human germline biallelic loss-of-function <i>OSMR</i> variants cause severe allergic disease.

Journal of human immunity·2026
Same author

Sinus mast cell accumulation and persistence suggest a unique endotype in toxin exposure-associated chronic rhinosinusitis.

The Journal of clinical investigation·2026
Same author

MRGPRX2-expressing mast cells are increased in the GI tract of individuals with active inflammatory bowel disease and hereditary α-tryptasemia.

Frontiers in allergy·2026
Same author

Extended clinical phenotypes and long-term outcomes of phosphoglucomutase-3 deficiency.

Journal of human immunity·2026
Same author

MRGPRX2-expressing mast cells are increased in the GI tract of individuals with active inflammatory bowel disease and hereditary α-tryptasemia.

medRxiv : the preprint server for health sciences·2026
Same author

Alpha-Tryptase Overexpression as a Modifier of Mast Cell-Mediated Reactions.

The journal of allergy and clinical immunology. In practice·2025
Same journal

Anaphylaxis: State-of-the-Art.

Immunology and allergy clinics of North America·2026
Same journal

Upending Impending Doom.

Immunology and allergy clinics of North America·2026
Same journal

Mast Cell Activation Syndrome and Mimickers.

Immunology and allergy clinics of North America·2026
Same journal

Emerging Therapies for Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Novel Epinephrine Delivery Devices.

Immunology and allergy clinics of North America·2026
Same journal

Venom Anaphylaxis.

Immunology and allergy clinics of North America·2026
See all related articles
  1. Home
  3. Hereditary Alpha-tryptasemia (hαt) As A Risk Modifier For Severe Anaphylaxis.
  1. Home
  3. Hereditary Alpha-tryptasemia (hαt) As A Risk Modifier For Severe Anaphylaxis.

Related Experiment Video

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.2K

Hereditary Alpha-Tryptasemia (HαT) as a Risk Modifier for Severe Anaphylaxis.

Abigail Lang1, Wajiha Kazmi2, Jonathan J Lyons3

  • 1Division of Allergy and Immunology, Ann and Robert H. Lurie Children's Hospital of Chicago, Department of Pediatrics at Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Immunology and Allergy Clinics of North America
|April 3, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Hereditary alpha-tryptasemia (HαT), a common genetic trait, increases alpha-tryptase. This condition is linked to more severe allergic reactions, including anaphylaxis and venom allergies, highlighting its role in immune responses.

Keywords:
AnaphylaxisDrug allergyFood allergyHereditary alpha-tryptasemiaMastocytosis

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.9K

Related Experiment Videos

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.2K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.9K

Area of Science:

  • Genetics
  • Immunology
  • Allergy Research

Background:

  • Hereditary alpha-tryptasemia (HαT) is a common autosomal dominant genetic trait.
  • It arises from increased copy numbers of the TPSAB1 gene, which encodes α-tryptase.
  • Elevated α-tryptase expression can influence mast cell reactions and anaphylaxis severity.

Purpose of the Study:

  • To investigate the role of HαT as a risk modifier in allergic reaction severity.
  • To explore the association between HαT, α-tryptase levels, and severe allergic responses.
  • To evaluate tryptase genotyping as a potential biomarker for stratifying allergy risk.

Main Methods:

  • Genetic analysis to determine HαT status.
  • Assessment of α-tryptase levels.
  • Clinical data review for allergic reaction severity.

    • Main Results:

    • HαT is an independent risk modifier for severe reactions in Hymenoptera venom allergy and systemic mastocytosis.
    • Emerging evidence links HαT and α-tryptase to increased risk of severe reactions to other allergens.
    • Tryptase genotyping shows promise as a biomarker for risk stratification.

    Conclusions:

    • HαT significantly impacts allergic reaction severity.
    • α-tryptase levels are associated with heightened risks in various allergic conditions.
    • Tryptase genotyping may offer future utility in predicting and managing severe allergic reactions.